Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Director Sells 500 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 500 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $33.30, for a total value of $16,650.00. Following the sale, the director now owns 4,026 shares of the company’s stock, valued at approximately $134,065.80. This represents a 11.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

USANA Health Sciences Stock Down 1.9 %

Shares of USNA traded down $0.62 during trading hours on Wednesday, reaching $32.49. 189,849 shares of the company traded hands, compared to its average volume of 176,090. The business has a fifty day moving average price of $32.86 and a 200-day moving average price of $36.08. USANA Health Sciences, Inc. has a 12-month low of $27.71 and a 12-month high of $50.32. The stock has a market capitalization of $619.32 million, a P/E ratio of 11.48, a P/E/G ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, research analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

Institutional Investors Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of USNA. R Squared Ltd acquired a new stake in USANA Health Sciences during the 4th quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC purchased a new position in shares of USANA Health Sciences during the third quarter worth $30,000. KBC Group NV lifted its position in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in USANA Health Sciences in the fourth quarter valued at $83,000. Finally, Quantbot Technologies LP purchased a new stake in USANA Health Sciences in the fourth quarter valued at $132,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.